In the informative webinar hosted by Dr. Patrick Short, Co-founder and CEO of Sano Genetics, guest Dr. Andrea Gropman explored the profound impact of genetics and genomics on modern medical practice. The discussion provided valuable insights into the journey of translating genetic discoveries from the laboratory to the bedside, particularly focusing on neurogenetics and metabolic disorders.
Last week, Sano had the privilege of travelling to Boston for the Chief Medical Officer Summit 360°, where our Co-founder and COO, Charlotte Guzzo, shared her expertise on a panel focused on practical approaches to patient engagement. This event provided a platform for rich discussions on the shifting paradigms of drug development and precision medicine. Here, we’ll share an overview of key discussions and insights from the conference, emphasising the innovative strategies highlighted during the panels.
At Sano, we are constantly exploring new ways to use our technology expertise to make a meaningful impact on healthcare. That’s why we’re excited about our partnership with the Lupus Research Alliance (LRA) on a profoundly important project: the Lupus Nexus initiative. This collaboration represents a significant step forward in our efforts to contribute to critical advancements in the field of lupus research.
Natural history studies are instrumental in advancing precision medicine by offering a nuanced understanding of the patient journey across various diseases, including Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, and Huntington's Disease. This blog post explores the crucial role these studies play in disease modelling and the development of precisely targeted treatments within the realm of precision medicine.
This webinar, co-hosted by Sano Genetics and PrecisionLife, highlighted the complex nature of long Covid, which affects up to 30% of Covid-19 survivors and presents with more than 50 symptoms. The discussion brought to light the limitations of traditional genomic research, which has struggled to identify significant genetic risk factors, and underscored the necessity for innovative methodologies in understanding and treating this condition.
Liver disease remains one of the leading causes of morbidity and mortality worldwide, presenting complex challenges in healthcare due to its multifaceted nature and often silent progression. Advancements in genetic research have begun to illuminate the pathways through which liver diseases develop, revealing that conditions like metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), are not only influenced by lifestyle but also by genetic predispositions.
At Sano, our mission to accelerate the world’s transition to personalised medicine hinges on precise, individualised insights from vast amounts of health data. Understanding the sensitive nature of this data, we've committed to the highest standards of privacy and data protection, as detailed in our latest whitepaper, "Sano’s privacy promise."
This webinar focused on the potential of artificial intelligence (AI) in drug development, particularly within the realms of precision medicine. Hosted by Charlotte Guzzo, COO of Sano, the session featured insights from top industry experts who discussed their personal journeys at the intersection of technology and healthcare, the challenges of integrating AI into drug development, and the cutting-edge innovations their companies are pioneering.
Natural history studies play a pivotal role in deepening our understanding of diseases by observing them in their unmodified state. These studies offer invaluable insights by serving as "natural" comparisons for assessing the impact of treatments, thus playing a crucial role during the drug development process and in comprehending how diseases evolve without medical intervention. They act as fundamental benchmarks to gauge the effectiveness of new therapies.
In this webinar, Sano’s Senior Project Manager Clare Clarke shares the approach Sano employs to achieve its mission of accelerating the world’s transition to precision medicine. She outlines the seamless integration of recruitment, biomarker testing, and engagement within research trials, and provides an overview of Sano’s technology. This is the first in a series of webinars that will showcase various aspects of Sano’s product.